Oct 07, 2023 Leave a message

Light-controlled Immune Switch Can Be Used To Kill Cancer Cells

Recently, researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences (CAS) and the University of Chinese Academy of Sciences (UCAS) have created a novel whole tumor cell vaccine (TCV) platform, which can achieve optimal pulsed immune enhancement through the implementation of near-infrared (NIR) illumination at the vaccination site on demand according to the tumor progression. The research results have been published online in Nature Communications.
What is a whole tumor cell vaccine? What are the advantages of whole tumor cell vaccine over other tumor vaccines? What are the future application scenarios of this vaccine? On August 21, a reporter from Science and Technology Daily interviewed the experts who carried out this research.
Whole tumor cell vaccine has the potential of individualized precision therapy
Tumor vaccines have long been considered a promising form of tumor immunotherapy, which can use the body's immune system to fight tumor cells. Among tumor vaccines, whole tumor cell vaccines are a classic type of individualized tumor immunotherapy.
"Specifically, whole tumor cell vaccines are tumor vaccines obtained by inactivating whole tumor cells using physical or chemical means." Yanlin Lv, co-first author of the paper and associate researcher at the Institute of Process Engineering, told reporters that the inactivation treatment causes tumor cells to lose their intrinsic tumorigenicity but retains their immunogenicity, so the whole tumor cell vaccine has a full set of tumor-specific and tumor-associated antigens that can elicit a specific immune response from the body.
After vaccination, the tumor antigens of the vaccine will be released, inducing antigen-presenting cells (a class of immune cells) to recognize, uptake and present them, and then activating the body's immune system to specifically kill tumor cells, thus inhibiting the growth of the tumor or eliminating the tumor.
In Lv Yanlin's opinion, compared to other tumor vaccines, whole tumor cell vaccines have three major advantages. "Firstly, in terms of preparation, whole tumor cell vaccines are simple, inexpensive and easy to obtain raw materials; at the same time, whole tumor cell vaccines contain all the antigens of tumors, which can avoid the complex procedure of identifying tumor antigens, and can induce a multivalent immune response, reducing the possibility of immune escape." What's more, the whole tumor cell vaccine has more potential for individualized precision therapy because it contains tumor autologous antigens, Lv Yanlin said.
However, there are two sides to everything, and whole tumor cell vaccines have their drawbacks: their immunogenicity is weak and the immune responses they elicit vary greatly from one individual to another. Therefore, there is an urgent need to develop new concepts and technologies through interdisciplinary cross-disciplinary development in order to realize on-demand immunopotentiation.
Led by Ma Guanghui, an academician of the Chinese Academy of Sciences and a researcher of the Institute of Process Engineering, and Wei Wei, a researcher of the Institute of Process Engineering, the researchers of the Institute, based on the research foundation of tumor immunotherapy and biological dosage form engineering for many years, carried out cross-collaborative research on photo-functional materials and biomimetic dosage form engineering with Tian Zhiyuan, a professor of the School of Chemical Sciences of the University of Chinese Academy of Sciences.
Solving the two major problems of weak immunogenicity and uncontrollable in vivo immune response
Talking about the preparation of the whole tumor cell vaccine, Meng Jiaqi, the co-first author of the paper and a doctoral student at the University of Chinese Academy of Sciences, gave the reporter a detailed description of the preparation of the inactivated vaccine. She said, "Vaccine inactivation usually has chemical inactivation, physical inactivation and other ways, the core idea is to destroy the protein structure of the cell, so that it loses biological activity. Chemical inactivation is accomplished through chemical reagents, commonly used chemical reagents include formaldehyde solution, etc.; physical inactivation is done through high temperature, ultraviolet light, repeated freezing and thawing, and other physical methods to deal with the cells."
Meng Jiaqi explained that in the preparation process, after the traditional whole tumor cell vaccine is inactivated, the cell structure may be damaged, there are problems such as antigen leakage or loss, which in turn is manifested in causing a weak immune response in the body. In the process of use, traditional whole tumor cell vaccines still have the problem of stimulating a weak immune response, which is mainly reflected in the low recruitment efficiency of antigen-presenting cells, weak antigen-presenting ability, and uncontrollable immune response.
In this research work, the researchers made a special design to solve the above problems. "We first loaded nanoparticles with photothermal effects into tumor cells and induced them to produce heat shock proteins through near-infrared light exposure, which can act as endogenous immune adjuvants to enhance the immune response." Dr. Powell, co-first author of the paper and a member of the School of Chemical Sciences at the University of Chinese Academy of Sciences, said, "Afterwards, we inactivated the treated tumor cells by freeze-thawing, i.e., we obtained the light-controlled whole tumor cell vaccine (LN-TCV), which ensures that the tumor-associated antigens can be retained in their entirety. "
After a single vaccination immunization, the research team was able to generate a locally induced, mild inflammatory response by applying near-infrared laser irradiation to the vaccination site. This process promotes the recruitment, activation and presentation of dendritic cells, which then activate T cells in the lymph nodes for subsequent tumor cell killing.
On this basis, in order to monitor the rate of tumor growth, the research team also proposed an indicator - Fluctuation in Tumor Growth Rate (FTGR). Tumor growth rate fluctuation can be achieved by repeated near-infrared laser irradiation at the inoculation site, which provides a standard for reasonably enhancing the immune response on demand, allowing the pulse booster to precisely fit the developmental process of the tumor.
Photo-controlled whole tumor cell vaccine results still belong to preclinical research
According to Yanlin Lu, this research solves the problem of weak immunogenicity of traditional whole tumor cell vaccines, as well as the problem of uncontrollable immune response in vivo.
"In the construction process of the photo-controlled whole tumor cell vaccine, we induced the production of endogenous adjuvant by photothermal nanoparticle loading and irradiating the tumor cells with near-infrared laser. Usually endogenous adjuvants are produced by transgenesis, and our approach is simpler, less time-consuming and easier to handle than the virus-mediated transgenesis process." Yanlin Lu said.
Meanwhile, the research team used two freezes and thaws to inactivate the tumor cells, which on the one hand ensured that all the tumor-associated antigens could be retained and not leaked; on the other hand, the vaccine prepared by this method ensured that the tumor antigens could be stored for a long period of time at the vaccination site.
In addition, the use of near-infrared light, a simple and non-invasive method to manipulate the immune response, is a major innovation of this study.
"After a single administration of a photocontrolled whole tumor cell vaccine, irradiation of the vaccination site with a near-infrared laser induces local heating, which creates a local mild inflammatory environment, which promotes the recruitment of antigen-presenting cells and increases the extent of the anti-tumor immune response, and as the anti-tumor progression is monitored, the vaccine site can be re-irradiated by near-infrared light again at the necessary time to further stimulate the immune response to achieve tumor suppression or clearance." Powell explains.
In Yanlin Lu's opinion, this new whole-tumor cell vaccine platform explores the feasibility of optically manipulating the immune response, which has strong potential and bright prospects for clinical translation. "In the future, this platform has a lot of room for development. The tumor microenvironment is very complex, and we can expand the vaccine from a single tumor cell to a variety of mixed cells of the tumor tissue, which may provide the immune system with a richer antigen library containing more antigens, offering the possibility of activating a more individualized and stronger immune response, further improving and enhancing the therapeutic effect." She said.
In the future, lasers may be replaced by light-emitting diodes (LEDs) during clinical translation, and researchers may design remote-controlled and wearable patch LEDs to further improve patient compliance and clinician maneuverability. Yanlin Lu said, "We can even envision a future in which patients vaccinated with whole-tumor cell vaccines can receive telemedicine from the comfort of their homes and be treated with the help of their smartphones, thus effectively activating immune responses and personalized medicine in an instantaneous operation."
Notably, the researchers also emphasized that the findings are still preclinical and the actual clinical efficacy remains to be further verified. Translated with www.DeepL.com/Translator (free version)

Send Inquiry

whatsapp

Phone

E-mail

Inquiry